Opendata, web and dolomites

c4c SIGNED

conect4children (COllaborative Network for European Clinical Trials For Children)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "c4c" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE PENTA - FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV ANDRELATED DISEASES - ONLUS 

Organization address
address: CORSO STATI UNITI 4
city: PADOVA
postcode: 35127
website: www.penta-id.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://conect4children.org/
 Total cost 140˙496˙816 €
 EC max contribution 67˙000˙000 € (48%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-10-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2024-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE PENTA - FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV ANDRELATED DISEASES - ONLUS IT (PADOVA) coordinator 34˙011˙250.00
2    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 4˙190˙000.00
3    OSPEDALE PEDIATRICO BAMBINO GESU IT (ROMA) participant 2˙640˙250.00
4    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 2˙268˙750.00
5    FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS IT (VALENZANO BARI) participant 2˙103˙750.00
6    SERVIZO GALEGO DE SAUDE ES (Santiago de Compostela) participant 1˙871˙250.00
7    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 1˙742˙500.00
8    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 1˙602˙500.00
9    ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH DE (STUTTGART) participant 1˙452˙500.00
10    HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ FI (HELSINKI) participant 1˙401˙250.00
11    TARTU ULIKOOL EE (TARTU) participant 1˙174˙750.00
12    FUNDACIO SANT JOAN DE DEU ES (Esplugues de Llobregat) participant 1˙098˙500.00
13    UNIVERSITEIT GENT BE (GENT) participant 966˙250.00
14    SIOP EUROPE ASBL BE (BRUXELLES) participant 892˙500.00
15    UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK IE (Cork) participant 744˙750.00
16    UNIVERZITA KARLOVA CZ (PRAHA 1) participant 685˙000.00
17    ARISTOTELIO PANEPISTIMIO THESSALONIKIS EL (THESSALONIKI) participant 647˙500.00
18    Associação para Investigação e Desenvolvimento da Faculdade de Medicina PT (Lisbon) participant 647˙500.00
19    INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA PL (WARSZAWA) participant 647˙500.00
20    EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION FR (Paris) participant 578˙750.00
21    OKIDS GMBH AT (WIEN) participant 573˙750.00
22    ISTITUTO GIANNINA GASLINI IT (GENOVA) participant 571˙250.00
23    SWISS CLINICAL TRIAL ORGANISATION CH (BERN) participant 547˙500.00
24    ECNP RESEARCH AND SCHOLARSHIP STICHTING (DE ECNP RESEARCH AND SCHOLARSHIP FOUNDATION) NL (UTRECHT) participant 540˙000.00
25    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 535˙000.00
26    HELSE BERGEN HF*HAUKELAND UNIVERSITY HOSPITAL NO (BERGEN) participant 517˙500.00
27    GYERMEKGYOGYASZATI KLINIKAI VIZSGALOI HALOZAT HU (BUDAPEST) participant 511˙250.00
28    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 504˙250.00
29    HELIOS DR. HORST SCHMIDT KLINIKEN WIESBADEN GMBH DE (WIESBADEN) participant 410˙000.00
30    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 347˙500.00
31    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) participant 218˙750.00
32    ARSENAL.IT - CENTRO VENETO RICERCAE INNOVAZIONE PER LA SANITA DIGITALE IT (TREVISO TV) participant 187˙500.00
33    EUROPEAN CYSTIC FIBROSIS SOCIETY DK (KARUP) participant 168˙750.00
34    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
35    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
36    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
37    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
38    INSTITUT DE RECHERCHES INTERNATIONALES SERVIER FR (SURESNES) participant 0.00
39    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
40    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
41    PFIZER LIMITED UK (SANDWICH) participant 0.00
42    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00
43    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

Paediatric medicines development is embedded in the European policy, legislation and in the work of the pharmaceutical industry but currently the potential of this effort is not realised. The conect4children (c4c) project will address the critical problems with the design, implementation and operational conduct of paediatric clinical trials, for example the fragmented and redundant efforts between sponsors, sites and countries. This project will generate a sustainable infrastructure that optimises the delivery of clinical trials in children through: a) a single point of contact for all sponsors, sites and investigators; b) efficient implementation of trials adopting consistent approaches, aligned quality standards and coordination of sites at national and international level; c) collaboration with specialist networks; d) high quality input to study design and preparation through rigorous strategic and operational feasibility assessment and e) the promotion of innovative methodologies. The project will be managed according to IMI2 best practice with a dedicated communications effort. The clinical trials infrastructure will be setup, implemented and tested by implementing 3-4 industry and at least 1 non-industry proof-of-viability studies. Expert advice groups will promote innovative methodologies and engagement with regulators. The business model for a sustainable infrastructure will be based on the European landscape of paediatric networks and available trial sites, the evaluation of services needs of sponsors of all kinds, and will be informed by the proof-of-viability studies. Supporting activities will include: data management (data about the trials and the network, including performance metrics for network management and promotion; handling trial data for non-industry sponsors; support for common data dictionaries); education and training. The voices of children, young people and their families will be central to the network.

 Deliverables

List of deliverables.
Set up the Educational Board, Validation of E-platform customization, YPAG’S approval of material; set-up “Train-the-Trainer” program and list the trainers in each c4c institution Other 2020-04-16 12:23:25
Leadership and membership expert groups database Other 2020-04-16 12:23:25
Evaluation of E-platform based on pilot course, with reports on questionnaires and statistic about a) instructional and interaction design of the environment; b) courses quality; c) users’ access and satisfaction Other 2020-04-16 12:23:25
First press release to launch the c4c project Other 2020-04-16 12:23:25

Take a look to the deliverables list in detail:  detailed list of c4c deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "C4C" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "C4C" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More